Crimagua Limited
Records under this name other than patents Crimagua Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,625,560 | Humanized Antibodies That Recognize Beta Amyloid Peptide conveyed to Janssen Alzheimer Immunotherapy, Wyeth - now held by Wyeth LLC In force · High confidence | In force | High confidence | |
| US 7,635,473 | Anti a Beta Antibody Formulation conveyed to Janssen Alzheimer Immunotherapy, Wyeth - now held by Wyeth LLC In force · High confidence | In force | High confidence | |
| US 9,644,025 | Immunotherapy Regimes Dependent on Apoe Status conveyed to Janssen Alzheimer Immunotherapy, Wyeth - now held by Janssen Sciences Ireland Uc In force · High confidence | In force | High confidence | |
| US 8,357,781 | Neuroactive Fragments of App now held by Janssen Alzheimer Immunotherapy Lapsed on the fee record Ended Jan 22, 2025 · High confidence | Lapsed on the fee record | Ended Jan 22, 2025 | High confidence |
| US 7,871,615 | Humanized Antibodies That Recognize Beta Amyloid Peptide conveyed to Janssen Alzheimer Immunotherapy, Wyeth - now held by Wyeth LLC Term ended Term ended Jun 19, 2024 · High confidence | Term ended | Term ended Jun 19, 2024 | High confidence |
| US 9,051,363 | Humanized Antibodies That Recognize Beta Amyloid Peptide conveyed to Janssen Alzheimer Immunotherapy, Wyeth - now held by Janssen Sciences Ireland Uc Term ended Term ended Jan 1, 2022 · Low confidence | Term ended | Term ended Jan 1, 2022 | Low confidence |
| US 8,613,920 | Treatment of Amyloidogenic Diseases conveyed to Janssen Alzheimer Immunotherapy, Wyeth - now held by Janssen Sciences Ireland Uc Lapsed on the fee record Ended Dec 24, 2021 · High confidence | Lapsed on the fee record | Ended Dec 24, 2021 | High confidence |
| US 8,318,164 | Anti a Beta Antibody Formulation conveyed to Janssen Alzheimer Immunotherapy, Wyeth - now held by Wyeth LLC Lapsed on the fee record Ended Nov 27, 2020 · High confidence | Lapsed on the fee record | Ended Nov 27, 2020 | High confidence |
| US 7,790,856 | Humanized Antibodies That Recognize Beta Amyloid Peptide conveyed to Janssen Alzheimer Immunotherapy, Wyeth - now held by Janssen Alzheimer Immunotherapy Term ended Ended no later than Nov 10, 2020 · Low confidence | Term ended | Ended no later than Nov 10, 2020 | Low confidence |
| US 8,227,403 | A-Beta Immunogenic Peptide Carrier Conjugates and Methods of Producing Same conveyed to Janssen Alzheimer Immunotherapy, Wyeth - now held by Janssen Sciences Ireland Uc Lapsed on the fee record Ended Jul 24, 2020 · Medium confidence | Lapsed on the fee record | Ended Jul 24, 2020 | Medium confidence |